Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sergey Medvedev

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Nature Communications|March 26, 2014
Ammonia as a case study for the spontaneous ionization of a simple hydrogen-bonded compoundTaras Palasyuk, Ivan Troyan, Mikhail Eremets, et al.
Gene|October 21, 2021
CRISPR-Cas9 mediated knockout of AnxA6 gene enhances influenza A virus replication in low-permissive HEK293FT cell lineAndrey Komissarov, Mariia Sergeeva, Evgenii Zhuravlev, et al.
Gynecologic Oncology|December 11, 2019
An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancerSarah B Gitto, Hyoung Kim, Stavros Rafail, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2023
A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 ExpressionSarah B Gitto, Margaret Whicker, Gareth Davies, et al.
Research Square|February 27, 2024
Targeting <i>CCNE1</i> amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATRHaineng Xu, Erin George, David Gallo, et al.
Frontiers in Immunology|November 29, 2023
Signaling via a CD28/CD40 chimeric costimulatory antigen receptor (CoStAR™), targeting folate receptor alpha, enhances T cell activity and augments tumor reactivity of tumor infiltrating lymphocytesMilena Kalaitsidou, Owen R Moon, Martina Sykorova, et al.
Nature Communications|April 1, 2025
Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATRHaineng Xu, Erin George, David Gallo, et al.
Nature Communications|July 26, 2020
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer modelsHyoung Kim, Haineng Xu, Erin George, et al.
Nature Communications|July 3, 2025
Correlation between the dome-shaped superconducting phase diagram, charge order, and normal-state electronic properties in LaRu<sub>3</sub>Si<sub>2</sub>KeYuan Ma, Igor Plokhikh, Jennifer N Graham, et al.
Iscience|July 18, 2024
CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and <i>CCNE1</i> amplified ovarian cancerHaineng Xu, Sarah B Gitto, Gwo-Yaw Ho, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Nature Communications|March 26, 2014
Ammonia as a case study for the spontaneous ionization of a simple hydrogen-bonded compoundTaras Palasyuk, Ivan Troyan, Mikhail Eremets, et al.
Gene|October 21, 2021
CRISPR-Cas9 mediated knockout of AnxA6 gene enhances influenza A virus replication in low-permissive HEK293FT cell lineAndrey Komissarov, Mariia Sergeeva, Evgenii Zhuravlev, et al.
Gynecologic Oncology|December 11, 2019
An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancerSarah B Gitto, Hyoung Kim, Stavros Rafail, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2023
A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 ExpressionSarah B Gitto, Margaret Whicker, Gareth Davies, et al.
Research Square|February 27, 2024
Targeting <i>CCNE1</i> amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATRHaineng Xu, Erin George, David Gallo, et al.
Frontiers in Immunology|November 29, 2023
Signaling via a CD28/CD40 chimeric costimulatory antigen receptor (CoStAR™), targeting folate receptor alpha, enhances T cell activity and augments tumor reactivity of tumor infiltrating lymphocytesMilena Kalaitsidou, Owen R Moon, Martina Sykorova, et al.
Nature Communications|April 1, 2025
Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATRHaineng Xu, Erin George, David Gallo, et al.
Nature Communications|July 26, 2020
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer modelsHyoung Kim, Haineng Xu, Erin George, et al.
Nature Communications|July 3, 2025
Correlation between the dome-shaped superconducting phase diagram, charge order, and normal-state electronic properties in LaRu<sub>3</sub>Si<sub>2</sub>KeYuan Ma, Igor Plokhikh, Jennifer N Graham, et al.
Iscience|July 18, 2024
CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and <i>CCNE1</i> amplified ovarian cancerHaineng Xu, Sarah B Gitto, Gwo-Yaw Ho, et al.
Pageof 5